ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Whole-genome sequencing of 508 patients identifies key molecular features associated with poor prognosis in esophageal squamous cell carcinoma.

Cui, Yongping; Chen, Hongyan; Xi, Ruibin; Cui, Heyang; Zhao, Yahui; Xu, Enwei; Yan, Ting; Lu, Xiaomei; Huang, Furong; Kong, Pengzhou; Li, Yang; Zhu, Xiaolin; Wang, Jiawei; Zhu, Wenjie; Wang, Jie; Ma, Yanchun; Zhou, Yong; Guo, Shiping; Zhang, Ling; Liu, Yiqian; Wang, Bin; Xi, Yanfeng; Sun, Ruifang; Yu, Xiao; Zhai, Yuanfang; Wang, Fang; Yang, Jian; Yang, Bin; Cheng, Caixia; Liu, Jing; Song, Bin; Li, Hongyi; Wang, Yi; Zhang, Yingchun; Cheng, Xiaolong; Zhan, Qimin*; Li, Yanhong山西省肿瘤医院; 中国医学科学院; 香港科技大学; the Hong Kong University of Science and Technology; The Hong Kong University of Science & Technology
Cell Research2020-10DOI: 10.1038/s41422-020-0333-6
13阅读
引用收藏
分享

摘要

Esophageal squamous cell carcinoma (ESCC) is a poor-prognosis cancer type with limited understanding of its molecular etiology. Using 508 ESCC genomes, we identified five novel significantly mutated genes and uncovered mutational signature clusters associated with metastasis and patients' outcomes. Several functional assays implicated that NFE2L2 may act as a tumor suppressor in ESCC and that mutations in NFE2L2 probably impaired its tumor-suppressive function, or even conferred oncogenic activities. Additionally, we found that the NFE2L2 mutations were significantly associated with worse prognosis of ESCC. We also identified potential noncoding driver mutations including hotspot mutations in the promoter region of SLC35E2 that were correlated with worse survival. Approximately 5.9% and 15.2% of patients had high tumor mutation burden or actionable mutations, respectively, and may benefit from immunotherapy or targeted therapies. We found clinically relevant coding and noncoding genomic alterations and revealed three major subtypes that robustly predicted patients' outcomes. Collectively, we report the largest dataset of genomic profiling of ESCC useful for developing ESCC-specific biomarkers for diagnosis and treatment.

相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Cell Research
发表日期
2020-10
卷期
第 30 卷, 第 10 期
页码
902-913
DOI
10.1038/s41422-020-0333-6
语言
ENGLISH
期刊收录
NSL.CAST-L.SCIE
期刊等级
1区
成果收录
PUBMED

作者

  • C

    Cui, Yongping (第一作者)

  • C

    Chen, Hongyan

    chinese academy of medical sciences

查看全部 38 位作者收起作者
  • X

    Xi, Ruibin

  • C

    Cui, Heyang

    hkust

  • Z

    Zhao, Yahui

    chinese academy of medical sciences

  • X

    Xu, Enwei

    shanxi cancer hospital

  • Y

    Yan, Ting

  • L

    Lu, Xiaomei

  • H

    Huang, Furong

    chinese academy of medical sciences

  • K

    Kong, Pengzhou

  • L

    Li, Yang

  • Z

    Zhu, Xiaolin

    chinese academy of medical sciences

  • W

    Wang, Jiawei

  • Z

    Zhu, Wenjie

  • W

    Wang, Jie

  • M

    Ma, Yanchun

  • Z

    Zhou, Yong

    hkust

  • G

    Guo, Shiping

    shanxi cancer hospital

  • Z

    Zhang, Ling

    hkust

  • L

    Liu, Yiqian

    hkust

  • W

    Wang, Bin

    hkust

  • X

    Xi, Yanfeng

    shanxi cancer hospital

  • S

    Sun, Ruifang

    shanxi cancer hospital

  • Y

    Yu, Xiao

    chinese academy of medical sciences

  • Z

    Zhai, Yuanfang

    hkust

  • W

    Wang, Fang

  • Y

    Yang, Jian

  • Y

    Yang, Bin

    shanxi cancer hospital

  • C

    Cheng, Caixia

  • L

    Liu, Jing

  • S

    Song, Bin

  • L

    Li, Hongyi

  • W

    Wang, Yi

    hkust

  • Z

    Zhang, Yingchun

    hkust

  • C

    Cheng, Xiaolong

  • Z

    Zhan, Qimin (通讯)

    hkust

  • L

    Li, Yanhong

  • L

    Liu, Zhihua (通讯)

    chinese academy of medical sciences

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417